Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non‐melanoma Skin Cancer: An Interrupted Time‐Series Analysis Using Swiss Claims Data
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.70005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Tamino Zappalà und 5 weiteren Autor:innen. Beteiligte Einrichtung: Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, S…. Hauptthemen laut MEDLINE: Hydrochlorothiazide, Antihypertensive Agents, Interrupted Time Series Analysis, Skin Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Basel Pharmacoepidemiology Unit (BPU).
Abstract (Originalsprache)
Purpose
Long‐term use of hydrochlorothiazide increases the risk of non‐melanoma skin cancer. We aimed to evaluate potential changes in the use of hydrochlorothiazide in Switzerland after a direct healthcare professional communication (DHPC) in November 2018 by Swissmedic.
Methods
We performed interrupted time‐series analyses using a large Swiss healthcare claims database (2015–2021). Within monthly intervals, we quantified the total number of claims and the total dispensed ‘defined daily doses’ (DDD) for preparations containing (1) hydrochlorothiazide, (2) angiotensin‐converting enzyme (ACE) inhibitors and angiotensin‐II‐receptor blockers (ARB), (3) calcium‐channel blockers (CCB) and (4) thiazide‐like diuretics per 10 000 persons. Using segmented linear regression, we quantified the pre‐DHPC trend, the immediate change and the post‐DHPC change in trend for total claims and DDD for the four drug classes weighted for the demographic distribution of the Swiss population.
Results
ACE inhibitors and ARB were the most frequently claimed antihypertensive drugs with 300–400 claims per 10 000 persons, which increased by 5.4% during the study period. The average number of hydrochlorothiazide claims (157/10 000 persons in 2015) declined by 35% between 2015 and 2021. The decrease started prior to the DHPC, but the DHPC was associated with an immediate 6.1% decline and an accelerated decline in claims over time after the DHPC (similar results for DDD). This coincided with a 23% increase in claims of CCB (dihydropyridine type) over 7 years, whereas use of other antihypertensives increased less.
Conclusion
Our results suggest that the DHPC by Swissmedic in 2018 accelerated a pre‐existing decline in the use of hydrochlorothiazide in Switzerland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
- Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
- Department of Health Sciences, Helsana Group, Zurich, Switzerland.
- Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.
ORCID-Profile: Tamino Zappalà, Anton Pottegård, Carola A Huber, Daphne Reinau, Christoph R Meier, Julia Spoendlin
Förderung
- Basel Pharmacoepidemiology Unit (BPU)
Zitieren
APA
Zappalà, T., Pottegård, A., Huber, C. A., Reinau, D., Meier, C. R., & Spoendlin, J. (2024). Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non‐melanoma Skin Cancer: An Interrupted Time‐Series Analysis Using Swiss Claims Data. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70005
Vancouver
Zappalà T, Pottegård A, Huber CA, Reinau D, Meier CR, Spoendlin J. Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non‐melanoma Skin Cancer: An Interrupted Time‐Series Analysis Using Swiss Claims Data. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70005
BibTeX
@article{Zappal2024,
author = {Zappalà, Tamino and Pottegård, Anton and Huber, Carola A and Reinau, Daphne and Meier, Christoph R and Spoendlin, Julia},
title = {Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non‐melanoma Skin Cancer: An Interrupted Time‐Series Analysis Using Swiss Claims Data},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.70005}
}
EUVIMED